Evidence map›Paper›PMID 24587168›Full record

ArticlePloS one2014

Computational prediction of neutralization epitopes targeted by human anti-V3 HIV monoclonal antibodies.

Evgeny Shmelkov, Chavdar Krachmarov, Arsen V Grigoryan, Abraham Pinter, Alexander Statnikov, Timothy Cardozo

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Evgeny ShmelkovDepartment of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, New York, United States of America.
Chavdar KrachmarovPublic Health Research Institute Center, Rutgers New Jersey Medical School, Newark, New Jersey, United States of America.
Arsen V GrigoryanDepartment of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, New York, United States of America.
Abraham PinterPublic Health Research Institute Center, Rutgers New Jersey Medical School, Newark, New Jersey, United States of America.
Alexander StatnikovCenter for Health Informatics and Bioinformatics, New York University School of Medicine, New York, New York, United States of America.
Timothy CardozoDepartment of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, New York, United States of America.
New York University · USRutgers, The State University of New Jersey · US

Funding

INSTITUTIONAL CLINICAL AND TRANSLATIONAL SCIENCE AWARDUL1RR029893 · NCRR · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CRONSTEIN, BRUCE NEIL · 2009 to 2011
$17.7M
Combined cocaine and HIV vaccineDP1DA036478 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CARDOZO, TIMOTHY J · 2013 to 2017
$4.7M
Novel epitopes that mediate broad neutralization of clade B and C HIV-1 isolatesU01AI078410 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI PINTER, ABRAHAM · 2008 to 2012
$3.3M
Optimizing protective vaccine targets in the V1/V2 domain of HIV-1 gp120R01AI102718 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI PINTER, ABRAHAM · 2012 to 2015
$2.7M
NCRR NIH HHS 1UL1RR029893NCRR NIH HHS UL1 RR029893NIAID NIH HHS AI078410NIAID NIH HHS R01 AI102718NIAID NIH HHS U01 AI078410NIDA NIH HHS DP1 DA036478PHS HHS R01A1084119
6 · The paper itself

Abstract

The extreme diversity of HIV-1 strains presents a formidable challenge for HIV-1 vaccine design. Although antibodies (Abs) can neutralize HIV-1 and potentially protect against infection, antibodies that target the immunogenic viral surface protein gp120 have widely variable and poorly predictable cross-strain reactivity. Here, we developed a novel computational approach, the Method of Dynamic Epitopes, for identification of neutralization epitopes targeted by anti-HIV-1 monoclonal antibodies (mAbs). Our data demonstrate that this approach, based purely on calculated energetics and 3D structural information, accurately predicts the presence of neutralization epitopes targeted by V3-specific mAbs 2219 and 447-52D in any HIV-1 strain. The method was used to calculate the range of conservation of these specific epitopes across all circulating HIV-1 viruses. Accurately identifying an Ab-targeted neutralization epitope in a virus by computational means enables easy prediction of the breadth of reactivity of specific mAbs across the diversity of thousands of different circulating HIV-1 variants and facilitates rational design and selection of immunogens mimicking specific mAb-targeted epitopes in a multivalent HIV-1 vaccine. The defined epitopes can also be used for the purpose of epitope-specific analyses of breakthrough sequences recorded in vaccine clinical trials. Thus, our study is a prototype for a valuable tool for rational HIV-1 vaccine design.

Indexed as

Computational BiologyAIDS VaccinesAmino Acid SequenceAntibodies, MonoclonalAntibodies, NeutralizingConserved SequenceEpitopesHIV-1HIV AntibodiesHIV Envelope Protein gp120Models, MolecularMolecular Sequence DataPeptide FragmentsProtein ConformationSpecies SpecificityThermodynamicsAIDS VaccinesAntibodies, MonoclonalAntibodies, NeutralizingEpitopesHIV AntibodiesHIV Envelope Protein gp120HIV envelope protein gp120 (305-321)Peptide Fragments

Identifiers

PMID24587168
PMCPMC3934971
OpenAlexW2005998665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.